Actelion confirms $2.5B offer for ZS Pharma

Actelion is often thrown around as a possible buyout target--most recently, for deal-hungry Shire. But the Swiss biotech has its sights set on a pickup of its own. It's discussing a $2.5 billion buyout of ZS Pharma, it confirmed Thursday, sending shares of its target soaring. More from FierceBiotech

Suggested Articles

FDA researchers uncover more concerns and fears among front-line workers and minority groups about a COVID-19 vaccine.

As COVID-19 vaccines advance, the FDA held an expert hearing Thursday to talk safety, efficacy, distribution plans and vaccine confidence—plus more. 

Moderna, racing ahead with COVID-19 vaccine R&D, completed enrollment for its late-stage trial—and moved one step closer to approval.